RT Journal Article SR Electronic T1 O-020 Head and Neck Endovascular Repair of Vascular Malformations JF Journal of NeuroInterventional Surgery JO J NeuroIntervent Surg FD BMJ Publishing Group Ltd. SP A12 OP A12 DO 10.1136/neurintsurg-2013-010870.20 VO 5 IS Suppl 2 A1 Yakes, W YR 2013 UL http://jnis.bmj.com/content/5/Suppl_2/A12.1.abstract AB Objective To determine the efficacy of ethanol embolotherapy of extracranial head and neck vascular malformations of all types, particularly after failure of other endovascular and surgical treatments. Methods One hundred and sixty-six patients (64 males, 102 females; mean age: 38 yrs) presented with extracranial arteriovenous malformations (AVMs) of the head and neck area. Over half of the patients had undergone previous failed therapies. All patients underwent ethanol embolotherapy under general anaesthesia. Forty-five patients had AVMs and 121 patients had venous malformations (VM). Results Of 45 AVM patients, 26 patients are cured (mean follow-up 2½ years); of 121 venous malformation patients, 65 are at end-therapy (mean follow-up 4½ years). The remaining patients are not at end-therapy and are being treated for their residual malformations. In AVM follow-up, arteriography is the main imaging modality to determine cure or residual AVM as MR is less sensitive in the evaluation of residual AVM. In VM follow-up, MR is the main imaging tool, particularly with T-2 fat suppression and/or STIR imaging. All patients demonstrated improvement post-therapy. Complications were 4.5%, to include bleeding (self-limited), partial 7th nerve palsy (with recovery), skin injury (not requiring skin grafts), infection, and pain. Conclusions Ethanol has proven its consistent curative potential at long-term follow-up for high-flow AVMs and low-flow VM lesions at long-term follow-up as lesions in the periphery. Complication rates remain low. The procedures are tolerated well by the patients and done on an out-patient basis. Prior surgery and embolisation procedures can cause difficulty in lesion access, but does not obviate further ethanol endovascular treatment. Disclosures W. Yakes: None.